Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BHV3000-301: Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine

Next Previous
X
Search
Trial Profile

BHV3000-301: Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rimegepant (Primary)
  • Indications Migraine; Migraine with aura; Migraine without aura
  • Focus Registrational; Therapeutic Use
  • Sponsors Biohaven Pharmaceuticals

    • Most Recent Events

    • 17 Feb 2023 Last checked against ClinicalTrials.gov record.
    • 10 Dec 2022 Results of pooled Subgroup Analyses From 3 Phase 3 studies(n=3507: NCT03235479, NCT03237845 and NCT03461757) assessing the the efficacy of rimegepant for the Acute Treatment of Migraine in patients with with 1 or 2 triptans and those without a history of insufficient response, including triptan-naive and current triptan users,presented at the 16th European headache federation COngress
    • 06 Jun 2021 Results of subgroup analyses from 3 phase 3 clinical trials assessing the efficacy of rimegepant for the acute treatment of migraine presented at the 63rd Annual Scientific Meeting of the American Headache Society

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top